Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer

NCT01322490 is registered in ClinicalTrials.gov with Bavarian Nordic as lead sponsor.

NCT NCT01322490
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01322490 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Phase 3 Efficacy Trial of PROSTVAC-V/F +/- GM-CSF in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate-Resistant Prostate Cancer
Lead sponsor
Bavarian Nordic
Phase
Phase 3
Overall status
Completed
Start date
November 28, 2011
Completion date
December 15, 2017
Enrollment
1,297 (actual)
Sites
220

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer metastatic